Skip to main content
. 2021 Sep 15;11:695006. doi: 10.3389/fonc.2021.695006

Figure 5.

Figure 5

Evaluation of the correlates of immune-check point inhibitors to signature scores across cancer types. (A) Distribution of the signature scores across 21 cancer types in The Cancer Genome Atlas (TCGA) dataset. The red dot within each cancer type denoted the median score; the orange line represented the 80th percentile score across all samples. (B) The proportion of high signature score (>80th percentile) samples was correlated with the reported objective response rates in a published paper (Pearson correlation, R=0.78, p<0.0001). ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; UCEC, uterine corpus endometrial carcinoma; UVM, uveal melanoma.